Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 166   

Articles published

BMY 50.19 -0.17 (-0.34%)
price chart
Institutional Move: Bristol Myers Squibb Company (BMY) Shareholder Cullinan ...
Cullinan Associates Inc increased its stake in Bristol Myers Squibb Company (BMY) by 17.84% based on its latest 2016Q2 regulatory filing with the SEC.
Biotech stock to Watch: Bristol-Myers Squibb Company (NYSE:BMY)  Is stories
Bristol-Myers Squibb Company (NYSE:BMY) Insiders Look Pessimistic About ...  Review Fortune
Most Active Options: Chesapeake Energy Corporation and Bristol-Myers Squibb Co
The 20 stocks listed in the table below have attracted the highest total options volume during the past 10 trading days. Stocks highlighted are new to the list since the last time the study was run, and data is courtesy of Schaeffer's Senior ...
Investor's Watch: Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Co (NYSE:BMY) share price plunged -0.94% or -0.47 points to reach at $49.77 during previous trading session.
Holder Worth Mentioning: Bristol Myers Squibb Co Com (BMY) Market Value Rose ...  Chester News
Current Bristol-Myers Squibb Company (NYSE:BMY) PT Means Stock Is Worth ...  Review Fortune
Stock Update (NYSE:BMY): Bristol-Myers Squibb Co Receives Positive CHMP ...
Bristol-Myers Squibb Co (NYSE:BMY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of adult patients with relapsed or ...
Bristol Waits For The Other PD-1 Shoe To Drop  Seeking Alpha
Stock Update (NYSE:BMY): Bristol-Myers Squibb Co and Nektar Therapeutics ...
Bristol-Myers Squibb Co (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214, as a potential combination ...
Big Pharma partners with another Bay Area company in cancer immunotherapy quest  San Francisco Business Times (blog)
Bristol-Myers to test Opdivo with Nektar drug for several cancers  Reuters
Options Traders Bear Down On Battered Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb Co (NYSE:BMY) is taking it on the chin, down nearly 10% at $49.99, after the company's lung cancer drug was shown up by a rival treatment in clinical trials.
CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10%  Motley Fool
Here's Why Bristol-Myers Squibb Co (BMY), Telefonica Brasil SA (ADR ...  Insider Monkey (blog)
Bristol-Myers Shares Plunge 7% as Lung Cancer Drug Fails Again
Bristol Myers logo Drug giant Bristol-Myers Squibb Co (NYSE:BMY) saw its shares fall up to 7% in early trading today, as news broke that an important immune-based therapy once again failed a lung cancer trial.
How a Merck cancer breakthrough caused Bristol-Myers' stock to plunge  MarketWatch
Bristol plunges, Merck jumps, on contrasting lung cancer data  Business Insider
Bristol-Myers Squibb Company (NYSE:BMY): Updated Analyst Ratings
Bristol-Myers Squibb Company (NYSE:BMY), with -8.74% losses in previous 5 sessions, is under coverage of 24 analysts who collectively assign a hold rating on stock.
Stock on Analyst Radar: Bristol-Myers Squibb Co (NYSE:BMY)  Post Registrar
Merck & Co., Inc. (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY) Present ...  Market Exclusive
Bristol-Myers Squibb Co (NYSE:BMY): Price Reaction History
Bristol-Myers Squibb Co (NYSE:BMY) soared 0.87% during previous trade, a total of 9,934,700 shares exchanged hands compared with its average trading volume of 11.01M shares whereas its relative volume is 0.91.
Upcoming Earnings Report: Bristol-Myers Squibb Company (NYSE:BMY)  The Voice Registrar
Traders Sell Bristol-Myers Squibb Co. (BMY) on Strength After Analyst Downgrade  BBNS
Analyst's Report Recap: Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Co (NYSE:BMY) soared 0.47% during previous trade, a total of 8,545,200 shares exchanged hands compared with its average trading volume of 11.21M shares whereas its relative volume is 0.77.
These Analyst Research Reports Are Worth Watching Bristol-Myers Squibb Co ...  Review Fortune
Revenue Estimates Analysis: Bristol-Myers Squibb Company (NYSE:BMY)  News Oracle